Literature DB >> 3183430

Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1.

E N Janoff1, J M Douglas, M Gabriel, M J Blaser, A J Davidson, D L Cohn, F N Judson.   

Abstract

We characterized the effect of infection with human immunodeficiency virus type 1 (HIV) on levels of total immunoglobulins and pneumococcal vaccine-specific immunoglobulins in 28 heterosexual and 25 homosexual men seronegative for HIV; 27 asymptomatic, seropositive homosexual men; and 21 patients with AIDS. Total serum IgG levels were increased in both HIV-seropositive groups compared with the HIV-seronegative men (P less than .001). Total IgM levels, however, were elevated only in the asymptomatic, HIV-seropositive men (P less than .08); total IgA levels were elevated only in the patients with AIDS (P less than .05). Vaccine-specific serum IgG, IgM, and IgA significantly increased over baseline three and six weeks after immunization in all groups (P less than .05). Responses to vaccine among the HIV-seronegative groups were similar but were greater for all antibody classes than were responses among the HIV-seropositive groups (P less than .05).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183430     DOI: 10.1093/infdis/158.5.983

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  Antibody responses in HIV infection.

Authors:  A J Pinching
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 3.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Measurement of pneumococcal capsular polysaccharide serotype-specific immunoglobulin G in human serum, a method for assigning weight-based units to proposed reference sera.

Authors:  K M Rudolph; A J Parkinson
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

6.  Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients.

Authors:  M R Dawood; B Conway; P Patenaude; F Janmohamed; J S Montaner; M V O'Shaughnessy; G W Hammond
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

Review 7.  Should patients positive for HIV infection receive pneumococcal vaccine?

Authors:  A Jain; S Jain; V Gant
Journal:  BMJ       Date:  1995-04-22

8.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

9.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

10.  CD11b-bearing mononuclear leucocytes and IgA levels in the staging of human immunodeficiency virus infection.

Authors:  J M Rivera-Guzmán; J R Regueiro; J Alcamí; A Arnaiz-Villena
Journal:  Experientia       Date:  1992-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.